FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950090868> ?p ?o ?g. }

• W2950090868 endingPage "671" @default.
• W2950090868 startingPage "671" @default.
• W2950090868 abstract "Background: Information on the molecular and phenotypic correlates of acute myeloid leukemia secondary (S-AML) to post-polycythemia vera (post-PV) and post-essential thrombocythemia (post-ET) myelofibrosis (known as secondary myelofibrosis, SMF) is scant. Aims: The primary objective of this study is to assess the incidence and outcome of S-AML in a large cohort of SMF. To find out predictors of S-AML occurrence, we performed a whole investigation of risk factors at the time of SMF, also applying established prognostic models. Methods: The MYSEC (Myelofibrosis Secondary to PV and ET Collaboration) project was recently updated collecting 805 SMF cases. We performed time-to-event (S-AML) analysis with Fine & Gray competing risks model using either death or the time of stem cell transplantation as competing risks. To explore whether IPSS (International Prognostic Scoring System), DIPSS (Dynamic IPSS) and MYSEC-PM (MYSEC-Prognostic Model) predicted S-AML occurrence, we calculated the difference in Cumulative Incidence Function (CIF) among risk categories for each score and applied Gray's model for testing the homogeneity of CIFs. Results: Within 805 SMF patients, 71 (8.8%) developed S-AML. Median time from SMF to S-AML evolution was 1.6 years (range: 0.6 - 14.6). The S-AML incidence rate was 2.3 x100 person-year of follow up (CI 95%: 1.8 - 2.9 x100). In univariate analysis, we found a direct association between increased S-AML risk and platelets <150 x10^9/l, hemoglobin <10 g/dl, PV/ET duration > 14 years, blasts ≥ 3% and non-CALR genotype, and an inverse association with the use of JAK2 inhibitors. In a multivariate analysis, only blasts ≥ 3%, PV/ET duration > 14 years and non-CALR genotype maintained their association with an increased risk of S-AML (Table 1). No impact on S-AML risk was found as for leukocyte count, spleen size, symptoms, karyotype and age at SMF; neither imbalance was evident for gender, previous PV versus ET, and cytoreduction.Among IPSS, DIPSS and MYSEC-PM, only the latter score stratified SMF patients for S-AML risk (P = 0.004) (Figure 1a). The estimated hazard ratios (HRs) when changing score category were: 1.55 (CI 95%: 0.69 - 3.50) from low to intermediate-1, 1.09 (CI 95%: 0.51 - 2.34) from intermediate-1 to intermediate-2, and 2.42 (CI 95%: 1.01 - 5.77) from intermediate-2 to high risk. Comparing to lower risk groups, HR for high risk cases was 4.07 (CI 95%: 1.66 - 10.03). Among S-AML, 65 (91.5%) patients died and the median survival was 3.9 months (CI 95%: 2.4 - 6.8) (Figure 1b).Summary/Conclusion: In our dataset of 805 SMF patients, ∼ 9% evolved into S-AML. The S-AML incidence rate was 2.3 x100 person-year and the median survival dismal. In a multivariate analysis, blasts ≥ 3%, non-CALR genotype and longer duration of PV/ET correlated with an increased risk of S-AML. Besides, our data supports the relevance of MYSEC-PM in predicting S-AML evolution, especially for the opposite categories of low and high risks." @default.
• W2950090868 created "2019-06-27" @default.
• W2950090868 creator A5000506070 @default.
• W2950090868 creator A5002094116 @default.
• W2950090868 creator A5002133396 @default.
• W2950090868 creator A5006810419 @default.
• W2950090868 creator A5009381933 @default.
• W2950090868 creator A5013539196 @default.
• W2950090868 creator A5018769277 @default.
• W2950090868 creator A5019208096 @default.
• W2950090868 creator A5026430732 @default.
• W2950090868 creator A5042150873 @default.
• W2950090868 creator A5046292780 @default.
• W2950090868 creator A5046772202 @default.
• W2950090868 creator A5052342373 @default.
• W2950090868 creator A5054304877 @default.
• W2950090868 creator A5055163444 @default.
• W2950090868 creator A5061636219 @default.
• W2950090868 creator A5065621786 @default.
• W2950090868 creator A5069072959 @default.
• W2950090868 creator A5071352662 @default.
• W2950090868 creator A5072073030 @default.
• W2950090868 creator A5072484806 @default.
• W2950090868 creator A5075657251 @default.
• W2950090868 creator A5082953818 @default.
• W2950090868 creator A5083259909 @default.
• W2950090868 creator A5089661579 @default.
• W2950090868 creator A5090834454 @default.
• W2950090868 creator A5091536542 @default.
• W2950090868 date "2019-06-01" @default.
• W2950090868 modified "2023-10-08" @default.
• W2950090868 title "PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT" @default.
• W2950090868 doi "https://doi.org/10.1097/01.hs9.0000564096.75769.8f" @default.
• W2950090868 hasPublicationYear "2019" @default.
• W2950090868 type Work @default.
• W2950090868 sameAs 2950090868 @default.
• W2950090868 citedByCount "2" @default.
• W2950090868 countsByYear W29500908682020 @default.
• W2950090868 crossrefType "journal-article" @default.
• W2950090868 hasAuthorship W2950090868A5000506070 @default.
• W2950090868 hasAuthorship W2950090868A5002094116 @default.
• W2950090868 hasAuthorship W2950090868A5002133396 @default.
• W2950090868 hasAuthorship W2950090868A5006810419 @default.
• W2950090868 hasAuthorship W2950090868A5009381933 @default.
• W2950090868 hasAuthorship W2950090868A5013539196 @default.
• W2950090868 hasAuthorship W2950090868A5018769277 @default.
• W2950090868 hasAuthorship W2950090868A5019208096 @default.
• W2950090868 hasAuthorship W2950090868A5026430732 @default.
• W2950090868 hasAuthorship W2950090868A5042150873 @default.
• W2950090868 hasAuthorship W2950090868A5046292780 @default.
• W2950090868 hasAuthorship W2950090868A5046772202 @default.
• W2950090868 hasAuthorship W2950090868A5052342373 @default.
• W2950090868 hasAuthorship W2950090868A5054304877 @default.
• W2950090868 hasAuthorship W2950090868A5055163444 @default.
• W2950090868 hasAuthorship W2950090868A5061636219 @default.
• W2950090868 hasAuthorship W2950090868A5065621786 @default.
• W2950090868 hasAuthorship W2950090868A5069072959 @default.
• W2950090868 hasAuthorship W2950090868A5071352662 @default.
• W2950090868 hasAuthorship W2950090868A5072073030 @default.
• W2950090868 hasAuthorship W2950090868A5072484806 @default.
• W2950090868 hasAuthorship W2950090868A5075657251 @default.
• W2950090868 hasAuthorship W2950090868A5082953818 @default.
• W2950090868 hasAuthorship W2950090868A5083259909 @default.
• W2950090868 hasAuthorship W2950090868A5089661579 @default.
• W2950090868 hasAuthorship W2950090868A5090834454 @default.
• W2950090868 hasAuthorship W2950090868A5091536542 @default.
• W2950090868 hasBestOaLocation W29500908681 @default.
• W2950090868 hasConcept C120665830 @default.
• W2950090868 hasConcept C121332964 @default.
• W2950090868 hasConcept C126322002 @default.
• W2950090868 hasConcept C143998085 @default.
• W2950090868 hasConcept C144301174 @default.
• W2950090868 hasConcept C2778729363 @default.
• W2950090868 hasConcept C2778837598 @default.
• W2950090868 hasConcept C2780007613 @default.
• W2950090868 hasConcept C2780076729 @default.
• W2950090868 hasConcept C2780240888 @default.
• W2950090868 hasConcept C2780817109 @default.
• W2950090868 hasConcept C2781057849 @default.
• W2950090868 hasConcept C38180746 @default.
• W2950090868 hasConcept C61511704 @default.
• W2950090868 hasConcept C71924100 @default.
• W2950090868 hasConcept C72563966 @default.
• W2950090868 hasConcept C88879693 @default.
• W2950090868 hasConceptScore W2950090868C120665830 @default.
• W2950090868 hasConceptScore W2950090868C121332964 @default.
• W2950090868 hasConceptScore W2950090868C126322002 @default.
• W2950090868 hasConceptScore W2950090868C143998085 @default.
• W2950090868 hasConceptScore W2950090868C144301174 @default.
• W2950090868 hasConceptScore W2950090868C2778729363 @default.
• W2950090868 hasConceptScore W2950090868C2778837598 @default.
• W2950090868 hasConceptScore W2950090868C2780007613 @default.
• W2950090868 hasConceptScore W2950090868C2780076729 @default.
• W2950090868 hasConceptScore W2950090868C2780240888 @default.
• W2950090868 hasConceptScore W2950090868C2780817109 @default.
• W2950090868 hasConceptScore W2950090868C2781057849 @default.
• W2950090868 hasConceptScore W2950090868C38180746 @default.
• W2950090868 hasConceptScore W2950090868C61511704 @default.

• next